Alcon: Q3 Earnings Insights

Shares of Alcon ALC rose 2.73% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 15.22% year over year to $0.39, which beat the estimate of $0.22.

Revenue of $1,818,000,000 declined by 1.25% year over year, which beat the estimate of $1,670,000,000.

Outlook

Alcon hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Technicals

52-week high: $68.11

Company's 52-week low was at $39.37

Price action over last quarter: Up 11.13%

Company Description

Alcon, headquartered in Fort Worth, Texas, is the global eye care leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with 41% of revenue in the U.S. market, and the firm has a strong presence in the European Union and Japan.